Dian Diagnostics Group Co. Ltd. Class A

Dian Diagnostics Group Co. Ltd. Class A

SSZSE:300244
19.24
CNY
-0.45
(-2.29%)
0.97EPS
26.71P/E
12.82BMarket Cap
Apr 09Next Earn

Total Valuation

CNY

As of September 30, 2026, Dian Diagnostics Group Co. Ltd. Class A carries a market capitalization of 12.82B, placing it among publicly traded companies globally. Its enterprise value stands at 14.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap12.82B
Enterprise Value14.95B

Important Dates

Dian Diagnostics Group Co. Ltd. Class A's next confirmed earnings release is scheduled for April 9, 2027.

Earnings Date4/9/2027

Share Statistics

As of September 30, 2026, Dian Diagnostics Group Co. Ltd. Class A has 624.98M shares outstanding.

Shares Outstanding624.98M

Valuation Ratios

As of September 30, 2026, Dian Diagnostics Group Co. Ltd. Class A trades at a trailing price-to-earnings ratio of 26.71. The price-to-sales ratio is 1.26, and the price-to-book ratio stands at 1.91.

PE Ratio26.71
PS Ratio1.26
PB Ratio1.91
P/TBV Ratio2.12

Enterprise Valuation

As of September 30, 2026, Dian Diagnostics Group Co. Ltd. Class A trades at an EV/EBITDA multiple of 18.10 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.50 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.10 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 14.95B versus a market cap of 12.82B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.50
EV / EBITDA18.10
EV / EBIT18.10

Financial Position

As of September 30, 2026, Dian Diagnostics Group Co. Ltd. Class A maintains a current ratio of 2.77, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 17.33, indicating elevated leverage, while an interest coverage ratio of 5.78 demonstrates adequate ability to service its debt obligations.

Current Ratio2.77
Quick Ratio0.42
Debt / Equity17.33
Debt / EBITDA1.85
Interest Coverage5.78

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 1.33M in revenue per employee across its workforce of 7,462.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee1.33M
Employee Count7,462.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Dian Diagnostics Group Co. Ltd. Class A recorded 199.82M in income tax expense. That works out to an effective tax rate of 25.15, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 794.57M, leaving 469.50M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax199.82M
Effective Tax Rate25.15

Stock Price Statistics

CNY

As of the close on November 17, 2026, Dian Diagnostics Group Co. Ltd. Class A's stock has gained approximately 19.06% over the past 52 weeks. The 50-day moving average sits at 19.88, while the 200-day moving average is 19.94.

52-Week Price Change19.06%
50-Day Moving Average19.88
200-Day Moving Average19.94

Income Statement

CNY

Over the twelve months ended September 30, 2026, Dian Diagnostics Group Co. Ltd. Class A generated 9.94B in revenue and converted that into 469.50M in net income, yielding earnings per share of 0.97. EBITDA reached 825.82M, while operating income came in at 884.39M.

Revenue9.94B
Gross Profit2.93B
Operating Income884.39M
Pretax Income794.57M
Net Income469.50M
EBITDA825.82M
EBIT825.82M
Earnings Per Share (EPS)0.97

Balance Sheet

CNY

As of September 30, 2026, Dian Diagnostics Group Co. Ltd. Class A holds 1.53B in cash and equivalents against 1.53B in total debt, resulting in a net debt position of -125.13M. Total book value stands at 6.72B, with working capital of 6.45B providing operational flexibility.

Cash & Cash Equivalents1.53B
Total Debt1.53B
Net Debt-125.13M
Equity (Book Value)6.72B
Book Value Per Share10.75
Working Capital6.45B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-249.21M

Margins

Over the twelve months ended September 30, 2026, Dian Diagnostics Group Co. Ltd. Class A posted a gross margin of 29.46, reflecting its pricing power and cost economics. The operating margin of 8.90 and net profit margin of 4.72 provide insight into operational efficiency.

Gross Margin29.46
Operating Margin8.90
Pretax Margin7.99
Profit Margin4.72
EBITDA Margin8.31

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Dian Diagnostics Group Co. Ltd. Class A paid dividends of 0.47 per share. The dividend payout ratio of 39.91 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 15.72, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Dian Diagnostics Group Co. Ltd. Class A shareholders.

Dividend Per Share0.47
Payout Ratio39.91
Shareholder Yield15.72

Stock Splits

Dian Diagnostics Group Co. Ltd. Class A's most recent stock split took place on May 9, 2016 with a 5:9 split ratio.

Last Split Date5/9/2016
Split Ratio5:9

Scores

As of September 30, 2026, Dian Diagnostics Group Co. Ltd. Class A has an Altman Z-Score of 3.59, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.59